Related Experiment Video

Updated: Nov 5, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.4K

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

Mingying Xie1, Xiaoling Xu2,3,4, Yun Fan2,3,4

  • 1Department of Medical Oncology, The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.

Frontiers in Oncology
|May 20, 2021
PubMed

Insights

KRAS mutations in non-small cell lung cancer (NSCLC) present poor prognosis. New KRAS G12C inhibitors and immunotherapy show promise for treating this challenging NSCLC subtype.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) is the predominant histological type of lung cancer, responsible for 85% of cases.
  • KRAS mutations are prevalent in NSCLC and are linked to poor patient outcomes due to limited treatment options.
  • KRAS-mutant NSCLC historically poses therapeutic challenges.

Purpose of the Study:

  • To review the pathogenesis of KRAS-mutant NSCLC.
  • To summarize the current treatment landscape for KRAS-mutant NSCLC.
  • To highlight recent advancements in targeted and immuno-therapies for KRAS-mutant NSCLC.

Main Methods:

  • Literature review of pathogenesis and treatment strategies.
  • Analysis of recent clinical trial data for KRAS G12C inhibitors (AMG510, MRTX849).
  • Evaluation of immunotherapy efficacy in KRAS-mutant NSCLC patients.

Main Results:

  • KRAS G12C inhibitors (AMG510, MRTX849) demonstrate potential therapeutic benefits in clinical trials.
  • Emerging evidence suggests immune efficacy in patients with KRAS mutations.
  • Targeted therapies and immunotherapies represent evolving treatment avenues.

Conclusions:

  • Targeted therapies, specifically KRAS G12C inhibitors, offer new hope for NSCLC patients with these mutations.
  • Immunotherapy is showing promise, suggesting a dual approach may be beneficial.
  • Further research into KRAS-mutant NSCLC pathogenesis and treatment is crucial.
Keywords:
AMG510KRAS-mutantMRTX849NSCLCimmunotherapytargeted therapy

More Related Videos

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.7K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.2K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
51.4K